Clinical Cancer Research
@CCR_AACR
Followers
8K
Following
857
Media
3K
Statuses
7K
Follow Clinical Cancer Research for innovative clinical trials and precision medicine. Published by @AACR.
Joined July 2018
Now online: T Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma https://t.co/ztnLyxt0eW
0
0
1
Now online: HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study https://t.co/Lbj9YGuS1g
0
0
0
Are you an early career researcher who has published in Clinical Cancer Research, or do you know someone who has? Nominations for the Clinical Cancer Research Early Career Award are open until Friday, January 9, 2026. Submit a nomination today: https://t.co/e0QDz6jSWM
0
3
1
Earlier this year, we interviewed Timothy A. Yap, the Journal's Editor-in-Chief. In this clip, Dr. Yap discusses the types of clinical studies and translational data ripe for publishing in Clinical Cancer Research. Learn More: https://t.co/e8LHcB4ZQD
0
1
3
Phase 2a Study (NCT03307746): Anti-CD27 immunostimulation in lymphoma.
aacrjournals.org
AbstractPurpose:. Varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show that agonistic CD27 antibodies can activate intratumoral T cells to release...
0
1
0
Read the latest Editors' Picks: Phase I Study of Izalontamab in Advanced Epithelial Tumor https://t.co/lRhR6v70hS Phase I Study of Ficerafusp Alfa with/without Pembrolizumab
aacrjournals.org
AbstractPurpose:. To evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of ficerafusp alfa (BCA101), a first-in-class bifunctional protein targeting EGFR and TGF-β, as monotherapy...
This month, the editors of AACR’s journals highlighted studies on how sucralose can limit response to immunotherapy, how caloric restriction can improve response to antiandrogen therapy, and more. Learn more on the #AACRBlog: https://t.co/4qRqRnug4o
0
2
4
Presubmission inquiries are now easier than ever: ➡️Log into the submission system: https://t.co/UWqPluVtgO ➡️Choose "presubmission" ➡️Provide a title, abstract, and one supporting file
0
1
7
Read the latest editors' picks: https://t.co/LxcncJyYqx Stay up to date with the @AACR journals by signing up for alerts: https://t.co/Rw4RMHMqgy
0
0
3
Phase 1/2 Study (NCT02824965): Immunomodulatory impact of CVA21 in NSCLC. https://t.co/JF6KPXykat
0
1
1
Phase 2 Study (NCT04053322): Olaparib, durvalumab and fulvestrant in breast cancer. https://t.co/62epgDQ9UW
0
1
3
Nominations for the 2026 Clinical Cancer Research Early Career Award are open! Our 2025 recipient, Joseph C. Murray, shares more about the questions that drive his research. The submission deadline for nominations is January 9, 2026. Learn more: https://t.co/3jOkR59X0k
0
0
2
Phase 1 Study (NCT04429542): Ficerafusp alfa with/without pembrolizumab in advanced solid tumors. https://t.co/edPjg4G7jp
0
4
10
Bridging EGFR/TGF-β signaling to bypass resistance to immune checkpoint blockade. https://t.co/zUWmC6eCJi
0
0
6
PRMT5 Inhibition Hits a Nerve (Sheath Tumor): A Targeted Strategy for MPNSTs.
aacrjournals.org
Summary. Protein arginine methyltransferase 5 inhibitors represent a promising therapeutic approach for multiple cancers, but their clinical development is hindered by toxicity to normal cells....
0
0
1
ICYMI: Nominations for the 2026 Clinical Cancer Research Early Career Award are open. The Award recipient will be invited to the Journals Reception that takes place during the AACR Annual Meeting and awarded $1,500. Find out more: https://t.co/nAKTxiRpIN
0
0
2
Clinical Cancer Research publishes innovative, high-impact clinical trials. Read the recently updated article collection: https://t.co/hPQCvQGWqb
0
0
3